Recent Company News

• 08:34 AM ET Mar 17, 2026
  

  Ascendis Pharma announces positive Week 52 topline results from New InsiGHTS Phase II trial ($231.03, 0.00)

• 05:12 PM ET Mar 02, 2026
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 08:48 AM ET Mar 02, 2026
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 08:04 AM ET Mar 16, 2026
  

  New two-year data from pivotal approach trial showing durable benefits of TransCon CNP (navepegritide) in children with achondroplasia shared at ACMG 2026 ($225.98, 0.00)

• 05:07 PM ET Mar 15, 2026
  

  Jefferies initiates ABVX, DSGN; assumes ALNY, ASND, COGT, others

• 11:55 AM ET Mar 02, 2026
  

  Transcript Intelligence: Ascendis Pharma at TD Cowen Health Care Conference ($234.16, +0.66)

• 09:39 AM ET Mar 02, 2026
  

  Transcript Intelligence: Ascendis Pharma YUVIWEL FDA Approval Call ($233.50, 0.00)

• 11:24 PM ET Feb 27, 2026
  

  StreetAccount Sector Summary - Healthcare Weekly Recap